Hinge Health, Inc.
HNGE
$94.90
+0.19%
Hinge Health, Inc. operates a technology-enabled care platform for treating and preventing joint and muscle pain, combining AI-powered motion tracking, wearable sensors, and a clinical care team to deliver virtual musculoskeletal (MSK) therapy to members while reducing costs for employers and health plans. The company is a leading pure-play digital MSK provider, differentiated by its proprietary patient movement data set and AI-driven exercise therapy engine, positioning it as a platform company at the intersection of digital health and value-based care. The current investor narrative centers on the company's rapid revenue growth and its transition to sustained GAAP profitability, with recent coverage highlighting its AI moat built on patient movement data and its appeal as a high-growth healthcare compounder. Debate among investors focuses on whether Hinge Health can maintain its ~47% year-over-year growth rate as it scales, defend against competition from larger virtual care platforms, and convert its strong gross margins into durable free cash flow following its May 2025 IPO.…
HNGE
Hinge Health, Inc.
$94.90
Related headlines
Investment Opinion: Should I buy HNGE Today?
Based on the synthesized data, Hinge Health earns a Buy rating, anchored by its exceptional 47.23% year-over-year revenue growth, a dramatic profitability inflection to a 19.27% net margin, and a fortress balance sheet with negligible debt. The analyst consensus is Buy (mean 1.56) with an average target of $107.73, implying 13.5% upside from the current price of $94.90, and the high target of $140.00 suggests 47.5% upside. The core thesis is that Hinge Health is a high-growth healthcare compounder with a durable AI moat and expanding margins, trading at a reasonable forward PE of 31.04 relative to its growth rate.
Supporting evidence includes: (1) revenue growth of 47.23% year-over-year, with consistent sequential gains; (2) gross margin expansion to 84.60% and net margin of 19.27% in Q1 2026; (3) trailing twelve-month free cash flow of $206.17 million, funding growth internally; (4) a PS ratio of 6.26, which is at the low end of its historical range (high of 41.96x) and below the industry premium despite superior growth; and (5) a debt-to-equity of 0.021, providing financial flexibility. These metrics compare favorably to the healthcare information services industry, which typically grows slower and has lower margins.
However, the biggest risks that could invalidate the thesis are: (1) a deceleration in revenue growth below 30%, which would challenge the premium valuation; (2) margin compression if competition intensifies or if the company invests heavily in growth; and (3) a broader market downturn that compresses high-multiple stocks. The rating would upgrade to a Strong Buy if the forward PE compresses below 25x while growth remains above 40%, or downgrade to a Hold if revenue growth falls below 30% or if gross margins decline below 80%. Relative to its history and peers, the stock appears fairly valued to slightly undervalued on a growth-adjusted basis, but the premium PS multiple warrants caution.
Sign up to view all
HNGE 12-Month Price Forecast
Hinge Health presents a compelling growth story with exceptional revenue growth, expanding margins, and a strong balance sheet, trading at a reasonable forward PE of 31.04. The stock's 123.40% six-month gain reflects strong momentum, but the premium PS of 6.26 and proximity to the 52-week high warrant caution. The base case (55% probability) targets $100-115, implying moderate upside, while the bull case (25%) could see $120-140 if growth accelerates. The bear case (20%) risks a decline to $70-85 if growth decelerates. I would upgrade to high confidence if Q2 2026 earnings show sustained >45% growth and margin expansion, and downgrade if revenue growth falls below 35% or gross margins decline below 80%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Hinge Health, Inc.'s 12-month outlook, with a consensus price target around $107.73 and implied upside of +13.5% versus the current price.
Average Target
$107.73
0 analysts
Implied Upside
+13.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$85 - $140
Analyst target range
Hinge Health is covered by 15 analysts, with a consensus recommendation of "Buy" (recommendation mean of 1.56 on a scale where 1 is Strong Buy and 5 is Strong Sell). The average price target is $107.73, implying approximately 13.5% upside from the current price of $94.90, with a low target of $85.00 and a high target of $140.00. The consensus leans bullish, supported by recent institutional ratings that show mostly Overweight and Buy actions from firms like Morgan Stanley, Keybanc, Barclays, and Canaccord Genuity, with no recent downgrades.
The target range of $85.00 to $140.00 represents a spread of 64.7% relative to the low target, indicating moderate uncertainty but overall strong conviction. The high target of $140.00 implies a forward PE of roughly 26.5x on estimated EPS of $5.29, assuming multiple expansion and continued revenue growth toward the high end of estimates ($2.14 billion), while the low target of $85.00 (below the current price) prices in potential margin compression or slower adoption. The estimated EPS average of $5.29 and revenue average of $2.01 billion for the current year suggest analysts expect robust growth, and the tight clustering of recent ratings (all Overweight/Buy) signals strong institutional support, though the wide target range warrants attention to execution risk.
Bulls vs Bears: HNGE Investment Factors
The bull case for Hinge Health is currently stronger, driven by exceptional revenue growth of 47.23% year-over-year, a dramatic profitability inflection with a 19.27% net margin, and a fortress balance sheet with negligible debt and $206.17 million in trailing free cash flow. The stock's 123.40% six-month gain and 66.75% one-year return reflect this momentum, and analysts are overwhelmingly bullish with a $107.73 average target. However, the bear case is not without merit: the stock trades at a premium PS of 6.26 versus industry averages, is near its 52-week high, and has a history of extreme volatility with a -48.03% max drawdown. The single most important tension is whether Hinge Health can sustain its ~47% growth rate and expanding margins as it scales, which is critical to justifying its valuation; any deceleration could trigger a sharp correction, while continued execution could drive further upside.
Bullish
- Hyper-Growth Revenue Trajectory: Q1 2026 revenue of $182.31 million grew 47.23% year-over-year from $123.83 million in Q1 2025, with consistent sequential gains from $139.10 million in Q2 2025 to $154.21 million in Q3 2025 to $170.73 million in Q4 2025. This sustained ~47% growth rate demonstrates strong adoption among employers and health plans and no signs of deceleration.
- Dramatic Profitability Inflection: Q1 2026 net income was $35.13 million (19.27% net margin) with an operating margin of 17.59% and EBITDA of $33.24 million (18.23% margin), a sharp reversal from the net loss of $1.84 million in Q3 2025. Gross margin expanded from 70.28% in Q2 2025 to 84.60% in Q1 2026, reflecting strong operating leverage.
- Fortress Balance Sheet and Cash Generation: Debt-to-equity is just 0.021, with total debt at only 2.12% of capitalization, and the current ratio is 1.47. Trailing twelve-month free cash flow is $206.17 million, and Q1 2026 free cash flow was $43.00 million, funding growth internally with $188.11 million in cash.
- Attractive Growth-Adjusted Valuation: The forward PE of 31.04 for a company growing revenue at 47% and generating an 84.6% gross margin is reasonable, especially with a PEG ratio that is not meaningful due to trailing losses but implies a low growth-adjusted multiple. The PS ratio of 6.26 is at the bottom of its historical range (high of 41.96x), suggesting the stock is undervalued relative to its own history.
Bearish
- Premium Valuation vs. Industry: The PS ratio of 6.26 and EV/Sales of 10.08 are at a premium to the healthcare information services industry average of 3-5x PS, implying a 25-100% premium. This leaves little room for execution missteps, and the negative trailing PE of -8.67 and EV/EBITDA of -6.49 highlight the reliance on future profitability.
- Extreme Price Volatility and Drawdown Risk: The stock has a max drawdown of -48.03% and is trading at $94.90, just 1.8% below its 52-week high of $96.66, which is 97.3% of its 52-week range. This proximity to resistance and the historical volatility suggest a high risk of sharp reversals, especially after a 123.40% six-month gain.
- Decelerating Momentum: While the stock is up 123.40% over six months, the 1-month gain has moderated to 7.28% and the 3-month gain to 36.70%, indicating a potential loss of momentum. This deceleration could signal mean reversion or consolidation, and without RSI data, the magnitude of the run-up suggests overbought conditions.
- Short Interest and Negative ROE: The short ratio of 2.86 indicates some bearish sentiment, and the ROE of -1.40 (due to historical losses) reflects past inefficiencies. Although recent profitability is positive, the negative ROE and the massive Q2 2025 loss of $575.65 million (driven by IPO-related stock-based compensation) highlight earnings volatility.
HNGE Technical Analysis
Hinge Health is in a powerful, sustained uptrend, with the stock up 66.75% over the past year and an extraordinary 123.40% over six months, reflecting a strong recovery from its post-IPO lows. At a current price of $94.90, the stock is trading at approximately 97.3% of its 52-week range (low of $30.08, high of $96.66), placing it just below its all-time high and signaling strong momentum but also potential overextension risk. This positioning near the top of the range suggests buyers remain firmly in control, though the proximity to resistance warrants caution for new entries without a pullback.
Short-term momentum remains positive but is decelerating relative to the longer-term trend: the stock is up 7.28% over the past month and 36.70% over three months, compared to the 123.40% six-month gain. This deceleration is not necessarily bearish, as it reflects consolidation after a parabolic run, but the 1-month relative strength versus SPY of +8.24% (SPY -0.96%) confirms continued outperformance. The 1-month change of +7.28% is well below the 3-month change of +36.70%, indicating that the pace of gains has moderated, which could signal either a healthy pause or the early stages of mean reversion; without RSI data, the magnitude of the run-up suggests overbought conditions may be developing.
Key technical support sits at the 52-week low of $30.08, with intermediate support likely around the $75-$80 area where the stock consolidated in July 2026. Resistance is defined by the 52-week high of $96.66; a breakout above this level on strong volume would confirm the uptrend's continuation and could open the door to new highs, while a breakdown below $75 would signal a deeper correction. The stock's beta is not available, but its max drawdown of -48.03% and short ratio of 2.86 indicate meaningful volatility and some short interest; the 48% peak-to-trough drawdown highlights the risk of sharp reversals, making position sizing critical despite the strong trend.
Beta
—
—
Max Drawdown
-48.0%
Largest decline past year
52-Week Range
$30-$97
Price range past year
Annual Return
+66.8%
Cumulative gain past year
| Period | HNGE Return | S&P 500 |
|---|---|---|
| 1m | +7.3% | -0.5% |
| 3m | +36.7% | +2.3% |
| 6m | +123.4% | +16.6% |
| 1y | +66.8% | +14.8% |
| ytd | +108.3% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HNGE Fundamental Analysis
Hinge Health's revenue trajectory is exceptionally strong, with Q1 2026 revenue of $182.31 million representing 47.23% year-over-year growth from $123.83 million in Q1 2025. Sequentially, revenue has grown from $139.10 million in Q2 2025 to $154.21 million in Q3 2025, $170.73 million in Q4 2025, and $182.31 million in Q1 2026, demonstrating consistent double-digit sequential gains and no signs of deceleration. The company operates as a single reportable segment, so all growth is driven by its core digital MSK platform, and the sustained ~47% growth rate implies strong adoption among employers and health plans, supporting a compelling investment case if the trend continues.
Profitability has inflected dramatically: Q1 2026 net income was $35.13 million (19.27% net margin) on a gross margin of 84.60%, up from a net loss of $1.84 million in Q3 2025 and a massive $575.65 million loss in Q2 2025 (driven by IPO-related stock-based compensation). Gross margin has expanded from 70.28% in Q2 2025 to 84.60% in Q1 2026, reflecting operating leverage and a shift toward higher-margin recurring revenue. The Q1 2026 operating margin of 17.59% and EBITDA of $33.24 million (18.23% EBITDA margin) confirm that the company has crossed into sustainable profitability, a critical milestone for a recently public company.
The balance sheet is exceptionally strong: debt-to-equity is just 0.021, with total debt representing only 2.12% of capitalization, and the current ratio stands at 1.47. Free cash flow on a trailing twelve-month basis is $206.17 million, and Q1 2026 free cash flow was $43.00 million, with operating cash flow of $43.08 million, indicating the company funds growth internally. Cash at the end of Q1 2026 was $188.11 million, down from $209.80 million in Q4 2025 due to $104.97 million in stock repurchases, but the company's negligible debt and strong cash generation provide ample financial flexibility. ROE is reported as -1.40 due to historical losses, but the recent profitability and positive ROA of 7.70% suggest improving returns on capital.
Quarterly Revenue
$182307000.0B
2026-03
Revenue YoY Growth
+47.2%
YoY Comparison
Gross Margin
84.6%
Latest Quarter
Free Cash Flow
$206166000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HNGE Overvalued?
Because Hinge Health reported positive net income in the most recent quarter ($35.13 million), the PE ratio is the appropriate primary metric; however, the trailing PE is negative (-8.67) due to the massive Q2 2025 loss, so the forward PE of 31.04 is the most relevant gauge. The forward PE of 31.04 versus a negative trailing PE reflects the market's expectation that the company will sustain and grow its recent profitability, with the gap implying that investors are pricing in continued earnings acceleration. The PEG ratio of -0.0025 is not meaningful given the negative trailing earnings, but the forward PE of 31x for a company growing revenue at 47% suggests a reasonable growth-adjusted valuation.
On a price-to-sales basis, HNGE trades at a PS ratio of 6.26, while the broader healthcare information services industry typically trades at PS multiples of 3-5x, implying a premium of roughly 25-100% depending on the peer set. The EV/Sales of 10.08 and EV/EBITDA of -6.49 (negative due to trailing losses) further highlight the premium, but this is justified by Hinge Health's 47% revenue growth, 84.6% gross margin, and 19.3% net margin, which are well above typical industry averages. The premium is also supported by the company's AI-driven moat and the large addressable market in digital MSK care, though investors should note that the PS ratio has compressed from 16.63x in Q1 2026 to 6.26x currently, reflecting the stock's price appreciation and revenue growth.
Historically, Hinge Health's PS ratio has ranged from a high of 41.96x in Q2 2023 to a low of 6.26x currently, placing the stock at the bottom of its historical valuation band. The PE ratio has also swung from negative territory to a forward PE of 31.04, and the price-to-book ratio of 9.72 is near the middle of its historical range (6.68 to 10.81). The current PS of 6.26 is significantly below the historical average, suggesting that either the market is undervaluing the company's growth or that the stock has become more reasonably priced after its massive run; given the strong fundamentals, the low PS relative to history could represent a value opportunity if growth persists.
PE
-8.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 22x~30x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-6.5x
Enterprise Value Multiple
Investment Risk Disclosure
Hinge Health's financial risks are relatively contained given its debt-to-equity of 0.021 and current ratio of 1.47, but the company's valuation is heavily dependent on sustaining its 47.23% revenue growth and 84.60% gross margin. A slowdown in revenue growth or margin compression could lead to a significant de-rating, as the forward PE of 31.04 already prices in continued earnings acceleration. Additionally, the company's historical earnings volatility, including a $575.65 million net loss in Q2 2025 due to IPO-related stock-based compensation, highlights the potential for large swings in profitability, and the negative ROE of -1.40 reflects past inefficiencies that must be overcome.
Market and competitive risks are significant: the stock trades at a PS ratio of 6.26 and EV/Sales of 10.08, well above the industry average of 3-5x PS, leaving it vulnerable to valuation compression if growth slows or if competitors erode its market share. The digital MSK space is becoming increasingly crowded, with larger virtual care platforms potentially leveraging their scale to compete on price. Furthermore, the stock's high volatility, evidenced by a max drawdown of -48.03% and a short ratio of 2.86, means it is sensitive to market sentiment and sector rotation, especially with the broader market (SPY) up only 15.01% over the past year while HNGE has surged 66.75%.
The worst-case scenario would involve a combination of decelerating revenue growth, margin pressure from competition, and a broader market downturn, leading to a sharp correction. In such a scenario, the stock could retest its 52-week low of $30.08, representing a potential downside of approximately 68% from the current price of $94.90. Even a more moderate bear case, aligning with the analyst low target of $85.00, implies a 10.4% decline. Given the stock's historical max drawdown of -48.03%, investors should be prepared for significant volatility and potential losses if the growth narrative falters.
FAQ
The key risks include: (1) Growth deceleration—if revenue growth falls below 30%, the premium valuation could compress sharply; (2) Competitive pressure—larger virtual care platforms could erode market share and margins, especially with a PS of 6.26 versus industry averages; (3) Volatility—the stock has a max drawdown of -48.03% and a short ratio of 2.86, making it susceptible to sharp reversals; and (4) Execution risk—the company must sustain its 47% growth and 84.6% gross margin to justify its forward PE of 31.04. These risks are ranked from highest to lowest severity, with growth deceleration being the most critical.
The 12-month forecast includes three scenarios: Bull case (25% probability) targets $120-140, driven by sustained >45% revenue growth and margin expansion; Base case (55% probability) targets $100-115, assuming growth moderates to 35-45% and profitability holds; Bear case (20% probability) targets $70-85, if growth falls below 30% and margins compress. The base case is most likely, with the key assumption that Hinge Health continues to execute on its growth trajectory and maintains its competitive edge. The average analyst target of $107.73 aligns with the base case, implying 13.5% upside from the current price of $94.90.
HNGE appears fairly valued to slightly undervalued on a growth-adjusted basis. The PS ratio of 6.26 is at the low end of its historical range (high of 41.96x) and below the industry premium of 3-5x PS, despite superior growth and margins. The forward PE of 31.04 is reasonable for a company growing revenue at 47% and generating an 84.6% gross margin. However, the EV/Sales of 10.08 and EV/EBITDA of -6.49 (due to trailing losses) suggest a premium. The market is pricing in continued execution, and if growth decelerates, the stock could be overvalued. Overall, the valuation is supported by fundamentals but leaves little room for error.
From a risk/reward perspective, HNGE offers a favorable but volatile opportunity. The stock trades at $94.90 with a forward PE of 31.04 and a PS of 6.26, which is reasonable given its 47.23% revenue growth and 19.27% net margin. Analyst consensus is Buy with an average target of $107.73 (13.5% upside), but the stock is near its 52-week high of $96.66 and has a history of a -48.03% max drawdown. It is a good buy for growth-oriented investors who can tolerate volatility and have a 2-3 year horizon, but conservative investors may want to wait for a pullback toward the $75-80 support level.
HNGE is more suitable for long-term investment (minimum 2-3 years) given its high growth stage, lack of dividend (payout ratio 0), and significant volatility (max drawdown -48.03%). The company is still scaling and reinvesting in growth, with a forward PE of 31.04 that requires time to be justified by earnings. Short-term trading is risky due to the stock's proximity to its 52-week high and potential for sharp reversals. A long-term holding period allows investors to benefit from the compounding of revenue growth and margin expansion, while weathering interim volatility. Earnings visibility is improving but remains limited for a recently public company (IPO May 2025).